Drug Trial Radar · NCT05684289
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Jan 3, 2023
Primary completion
May 2, 2023
Study completion May 2, 2023
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effect of BMS-986278 in healthy adult participants and Japanese participants.
Conditions
- Healthy Participants
Interventions
BMS-986278Drug
Specified dose on specified days
SildenafilDrug
Specified dose on specified days
PlaceboDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean placebo-corrected change from baseline in systolic blood pressure (SBP) (Part 1)Time frame: Up to 16 days
- Maximum observed plasma concentration (Cmax) (Part 2)Time frame: Up to 14 days
- Time of maximum observed plasma concentration (Tmax) (Part 2)Time frame: Up to 14 days
- Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) (Part 2)Time frame: Up to 14 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Altasciences Clinical Los Angeles, Inc
Cypress, California
Syneos Health Clinical Research Services, Llc
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.